Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL by Jürgen H Prochaska et al.
Prochaska et al. BMC Medicine  (2015) 13:14 
DOI 10.1186/s12916-015-0268-9RESEARCH ARTICLE Open AccessQuality of oral anticoagulation with
phenprocoumon in regular medical care and its
potential for improvement in a telemedicine-based
coagulation service – results from the prospective,
multi-center, observational cohort study
thrombEVAL
Jürgen H Prochaska1,2, Sebastian Göbel3,2, Karsten Keller1,2, Meike Coldewey1,2, Alexander Ullmann1,
Heidrun Lamparter1, Claus Jünger1, Zaid Al-Bayati1, Christina Baer1, Ulrich Walter1,3, Christoph Bickel4,
Hugo ten Cate1,5, Thomas Münzel2,1,3 and Philipp S Wild1,3,6*Abstract
Background: The majority of studies on quality of oral anticoagulation (OAC) therapy with vitamin K-antagonists
are performed with short-acting warfarin. Data on long-acting phenprocoumon, which is frequently used in Europe
for OAC therapy and is considered to enable more stable therapy adjustment, are scarce. In this study, we aimed to
assess quality of OAC therapy with phenprocoumon in regular medical care and to evaluate its potential for
optimization in a telemedicine-based coagulation service.
Methods: In the prospective observational cohort study program thrombEVAL we investigated 2,011 patients from
regular medical care in a multi-center cohort study and 760 patients from a telemedicine-based coagulation service
in a single-center cohort study. Data were obtained from self-reported data, computer-assisted personal interviews,
and laboratory measurements according to standard operating procedures with detailed quality control. Time in
therapeutic range (TTR) was calculated by linear interpolation method to assess quality of OAC therapy. Study
monitoring was carried out by an independent institution.
Results: Overall, 15,377 treatment years and 48,955 international normalized ratio (INR) measurements were
analyzed. Quality of anticoagulation, as measured by median TTR, was 66.3% (inte rquartile range (IQR) 47.8/81.9) in
regular medical care and 75.5% (IQR 64.2/84.4) in the coagulation service (P <0.001). Stable anticoagulation control
within therapeutic range was achieved in 63.8% of patients in regular medical care with TTR at 72.1% (IQR 58.3/
84.7) as compared to 96.4% of patients in the coagulation service with TTR at 76.2% [(IQR 65.6/84.7); P = 0.001)].
Prospective follow-up of coagulation service patients with pretreatment in regular medical care showed an
improvement of the TTR from 66.2% (IQR 49.0/83.6) to 74.5% (IQR 62.9/84.2; P <0.0001) in the coagulation service.
Treatment in the coagulation service contributed to an optimization of the profile of time outside therapeutic
range, a 2.2-fold increase of stabile INR adjustment and a significant decrease in TTR variability by 36% (P <0.001).
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Conclusions: Quality of anticoagulation with phenprocoumon was comparably high in this real-world sample of
regular medical care. Treatment in a telemedicine-based coagulation service substantially improved quality of OAC
therapy with regard to TTR level, frequency of stable anticoagulation control, and TTR variability.
Trial registration: ClinicalTrials.gov, unique identifier NCT01809015, March 8, 2013.
Keywords: Coagulation service, Epidemiology, Health care research, Oral anticoagulation, Quality of therapy,
TelemedicineBackground
Oral anticoagulation (OAC) therapy is the established
therapy to reduce the risk of thromboembolic events in
patients with atrial fibrillation [1]. Furthermore, it is
applied for secondary prevention in patients with throm-
bosis, pulmonary embolism, and prosthetic heart valves
[2]. In the future, the increasing age of the population
will lead to a higher prevalence of atrial fibrillation, the
most frequent indication for OAC therapy, and this will
strongly increase the need for long-term treatment with
oral anticoagulants [3]. Vitamin K antagonists (VKAs)
have been demonstrated to be effective oral anticoagu-
lant agents in reducing the risk of thromboembolic
events [4]. OAC therapy with VKAs has to be regularly
monitored and adjusted in order to maintain patients’
international normalized ratio (INR) levels within target
range and, consequently, to minimize adverse events.
The benefits of OAC therapy highly depend on quality
of treatment as measured by time in therapeutic range
(TTR) [5,6]. Calculation of TTR is an established sur-
rogate parameter to assess quality of anticoagulation
treatment with VKA [7] and is closely correlated with
outcome and frequency of thromboembolic events
[5,8]. In well-controlled and monitored clinical trials,
TTR of short-acting warfarin ranged from 55% to 67%
[6,9-11]. In contrast, levels of TTR of VKA treatment in
real world settings have been reported to be substantially
lower [12,13].
Different approaches have been made to optimize the
management of VKA-based OAC therapy ranging from
community-based settings to specialized care at anticoa-
gulation clinics and self-management education of patients.
Anticoagulation clinics introduced in the Netherlands have
been demonstrated to be associated with higher levels of
TTR [14] as compared to data from regular medical care
as well as to operate cost-effectively [15]. The choice of
VKA – either short-acting (e.g., acenocoumarol or war-
farin) or long-acting (e.g., phenprocoumon) – seems to
be also of importance due to inherent differences of
substances regarding pharmacodynamics and pharma-
cokinetics [16]. In the Netherlands, where anticoagula-
tion clinics provide the management of OAC therapy
nationwide, it has been demonstrated that quality of
therapy with long-acting phenprocoumon is superior toshort-acting acenocoumarol [17]. Worldwide, short-
acting warfarin is the most commonly prescribed oral
anticoagulant drug and has been studied intensively
[18]. Nevertheless, long-acting phenprocoumon is also
widely administered as oral anticoagulant agent [19]. Al-
though a class-effect for all VKA substances regarding
quality of therapy and clinical outcome has been postu-
lated, evidence from large-scale studies on quality of
OAC therapy with phenprocoumon reporting on real-life
practice (comprising all indications for OAC), clinical out-
come, and the potential for optimization of OAC therapy
by a coagulation service are, to the best of our knowledge,
currently not available in the literature.
The thrombEVAL study program represents a pro-
spective, multicenter observational study program which
was initiated in 2011 to comprehensively investigate OAC
therapy with phenprocoumon in the real-life setting. This
study took place against a background of increasing ap-
plication of new direct oral anticoagulants (currently
known as non-vitamin K dependent oral anticoagulants,
or NOACs [20]). This class of NOACs have been shown
to be effective and relatively safe as compared to warfarin
for several indications in large clinical trials. Although
without doubt the NOACs will replace a major fraction of
OAC treatment in patients with atrial fibrillation and ven-
ous thromboembolism, a significant proportion of these
patients cannot yet be treated with these drugs. Reasons
for choosing conventional VKA are severely impaired
renal function, expected lack of adherence to medication
that lacks routine control, and other concerns based
largely on exclusion criteria applied in the large NOAC
trials. In addition, patients with specific indications for
OAC, including mechanical heart valves, cannot yet be
treated with NOACs and it is uncertain whether this will
ever be possible. Thus, worldwide, there will remain an
indication for the use of well-controlled VKA, also in
the long run. In addition, it is questionable whether the
NOACs can really do without monitoring and dose
adjustment, which is one of the proposed advantages of
these agents. This advantage has now been called into
question because recent reports indicate that adjust-
ments of dabigatran dose in response to measurements
of plasma concentrations may have little impact on
stroke, but would strongly reduce the likelihood of major
Prochaska et al. BMC Medicine  (2015) 13:14 Page 3 of 11bleeds. These new results may indicate that, in case of a
high TTR, VKAs still may represent a cheap and reliable
alternative to NOACs for anticoagulation patients with,
for example, atrial fibrillation [21,22].
Herein, the quality of OAC treatment as assessed by
TTR in a population predominantly treated with phenpro-
coumon in regular medical care is reported. In order to
evaluate the potential for improvement of OAC therapy
with phenprocoumon, a specialized, telemedicine-based
coagulation service was comparatively investigated.
Methods
Study design
The background and design of the thrombEVAL study pro-
gram has been recently published elsewhere [23]. Briefly, it
comprises two observational prospective studies which are
performed within the German Health care system to inves-
tigate OAC treatment in a population which is predomin-
antly treated with phenprocoumon: a multi-center cohort
study with 21 study centers in regular medical care and a
single-center, multi-local cohort study in a specialized,
telemedicine-based coagulation service. Recruitment of
study participants for both cohorts was performed between
January 2011 and March 2013. Recruitment of patients for
observational investigation in the thrombEVAL study did
not influence management of OAC; prescription of drugs
and dosing was independently performed by GP and ambu-
latory working specialists. The final sample size of the regu-
lar medical care cohort comprised 2,011 study participants,
whereas 760 study participants were enrolled into the
coagulation service cohort [23].
Both cohorts received detailed clinical assessment at
study inclusion. In regular medical care, anticoagulation
control was recorded from documentation of OAC ther-
apy (e.g., anticoagulation pass). In the coagulation service,
anticoagulation control was permanently documented in
an electronic patient file for up to 2 years. To depict a
real-life scenario of anticoagulation practice, patients with
all indications for OAC therapy were eligible for study
enrolment. The trial was designed and led by a steering
committee of academic investigators. The study coordin-
ation, management of database, and primary analysis were
independently performed by the Center for Thrombosis
and Hemostasis (Mainz, Germany). Study monitoring was
carried out by an independent institution; all procedures
were performed according to the principles of good
clinical practice, STROBE guidelines, and the Declaration
of Helsinki. Approval of the local ethics committees
(medical association Rhine-Hesse, Germany; reference
no. 837.407.10.7415/7416) was obtained at all sites.
Study participants
Patients were recruited from a mid-western population of
predominant white European ancestry. In regular medicalcare, patients were eligible if OAC experience of at least 4
months duration was present in patients before study
enrolment. For the coagulation service cohort, VKA-naive
and VKA-experienced patients with envisaged treatment
duration of at least 3 months were eligible for study enrol-
ment. Reasons for exclusion were age <18 years and
contraindication to OAC treatment, e.g., pregnancy. Pa-
tients performing self-management of OAC (including
point-of-care blood withdrawal and VKA self-dosing)
were eligible for both cohorts. As this was an observa-
tional study, it did not interfere with any other medical
treatment. All study participants provided written, infor-
med consent.
Data assessment and study procedures
After study enrolment all study participants underwent
baseline investigation including clinical data assessment,
characteristics of OAC treatment, and acquisition of his-
tory of OAC (e.g., retrospective analysis of documenta-
tion of anticoagulation therapy). All data were obtained
according to standard operating procedures. Data assess-
ment was performed via structured computer-guided
analysis with checks for plausibility and validity.
At the coagulation service, OAC therapy was moni-
tored by nurses with training in hemostaseology and ex-
perienced physicians. All treatment information was
integrated into an electronic patient file, which could
be accessed via secured internet-connection and en-
abled telemedicine-based bridging of spatial and tem-
poral distances between patients, the coagulation
service, and other physicians in charge. Anticoagulant
dose-adjustment was based on the use of electronic
patient file data and integrated computer-assisted dos-
ing algorithms. Automated scheduling of OAC control
visits was established to prevent loss to follow-up and
improve patient adherence.
In the coagulation service, patients with self-management
of OAC had the possibility to enter INR values and dosing
schemes in the electronic patient file. All entries to the file
were inspected by the staff and, if necessary or requested
(e.g., problems with dosing or INR measurement, manage-
ment of bridging episodes), medical advice was provided.
Patients with self-management in regular medical care
performed INR measurements and adjustment of VKA
dosing independently.
INR values were obtained by analysis of anticoagula-
tion documentation (regular medical care cohort) and
electronic patient files (coagulation service cohort). Double
data entry of all paper-based documents into the study
database ensured high quality.
Statistical analysis
In this analysis, data on the primary short-term outcome
of the thrombEVAL study program, TTR, is reported.
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polation method [7]. In order to enable comparative ana-
lysis between the cohorts, TTR was calculated only in
patients with a consecutive lifetime use of VKA of at least
4 months. Patients with self-management of OAC were
analyzed separately. Specific target ranges were taken into
account according to indication for OAC. INR values were
taken into account for TTR calculation from the moment
that the first INR value was within therapeutic range.
Assessment of INR values identifying patients with stable
anticoagulation control was carried out separately. In
order to enable comparability between the cohorts, pa-
tients with self-management of OAC, or pretreatment
with OCA <4 months, or treatment in a specialized
outpatient clinic were analyzed separately from overall
comparison of standard care in both cohorts. Classifi-
cation of “patient with stable anticoagulation control”
(within individual therapeutic target range) required VKA
treatment of at least 28 days with three consecutive INR
measurements within therapeutic range. According to the
interpolation method for calculating time in therapeutic
range, the profile of time outside therapeutic range was
analyzed. Time of INR values outside the target range was
calculated and as was, subsequently, the distribution of
time above and below therapeutic range. TTR and time
outside therapeutic range were expressed as median
values with 25th/75th percentiles (interquartile range, IQR)
or as mean values ± standard deviation, respectively. For
TTR comparison between mixed samples of paired and
unpaired data a corrected z-test was used. Variability of
TTR profile and time outside therapeutic range between
regular medical care and the coagulation service, respect-
ively, were tested for by the one-sided Ansari-Bradley test,
a test for equivalence of variances in two distributions
[24]. Discrete variables were described by absolute and
relative frequencies. Fisher’s exact test was used to test for
proportion differences. The Mann-Whitney U-test was
performed to test for difference of medians in the two
groups; the z-test was used to test for difference of means
between groups of paired and unpaired data. All statistical
comparisons were two-tailed. P <0.05 was chosen as the
statistical significance threshold. Statistical data analysis




This analysis included the data of 2,771 patients that
were enrolled between January 2011 and March 2013,
including 2,011 participants in regular medical care and
760 in the coagulation service. A total of 15,377 treat-
ment years and 48,955 INR measurements were available
for analysis. For cross-sectional analysis, information on
regular medical care pretreatment data of coagulationservice patients was assigned to the regular medical care
cohort.
Anticoagulation pass was in use in 1,924 of 2,011 pa-
tients (95.7%) of regular medical care participants and
available for analysis in 1,774 of 1,924 patients (92.2%).
After analysis of OAC documentation calculation of TTR
according to linear interpolation method was applicable in
1,348 out of 1,774 patients of regular medical care (76.0%)
based upon anticoagulation pass documentation including
188 participants performing self-management of OAC.
For overall comparison of standard care in both cohorts,
1,160 patients of the regular medical care cohort were
finally eligible. In the coagulation service, electronic pa-
tient file data were available in all 760 (100%) patients.
Calculation of TTR was applicable in 723 of 760 (95.1%)
coagulation service patients, including 72 of patients with
self-management associated to the coagulation service. In
560 out of 723 participants (77.5%), regular medical care
inclusion criteria were applicable in order to perform ana-
lysis of both samples under equal assumptions.
Patient characteristics
The characteristics of the study participants are shown in
Table 1. Median age showed no differences between regu-
lar medical care and the coagulation service. Both cohorts
showed a high cardiovascular risk profile; hypertension
was the most common risk factor in both cohorts. Treat-
ment characteristics of the study participants are displayed
in Table 2. Phenprocoumon was the VKA of choice in
approximately 98% of all patients in both cohorts.
Quality of oral anticoagulation therapy
In comparison to regular medical care, median TTR was
9.2% higher in the coagulation service cohort (75.5%
(64.2/84.4) vs. 66.3% (47.8/81.9); P <0.001). Stable antic-
oagulation control was 1.5-fold more frequent in coagu-
lation service patients as compared to regular medical
care patients (96.4% vs. 63.8%; P <0.001) and variability
of TTR was reduced by 43.0% in coagulation service pa-
tients (14.4 vs. 25.2; P <0.001; Figure 1A). Sub-analysis
of patients with stable anticoagulation control revealed
similar findings: TTR was at higher level in the co-
agulation service cohort (76.2% (65.6/84.7) vs. 72.1%
(58.3/84.7); P <0.001) and variability of TTR was 31.9%
lower in coagulation service patients (13.0 vs. 19.1;
P <0.001; Figure 1B).
In coagulation service patients with pretreatment in
regular medical care, level of TTR at time of regular
medical care treatment was not statistically different
from the TTR of the regular medical care cohort (66.2% vs.
68.5%; P = 0.72). Prospective follow-up during treatment in
the coagulation service revealed a highly significant in-
crease of TTR upon coagulation service treatment (66.2%
(49.0/83.6) to 74.5% (62.9/84.2; P <0.001; Figure 1C). In






Male sex, % (no.) 62.2 (1,251) 52.0 (395)
Age, years 73.0 (66.0/79.0) 73.0 (63.0/80.0)
Body mass index, kg/m2 27.6 (24.7/31.1) 27.8 (24.9/31.2)
Classical cardiovascular
risk factors
Diabetes, % (no.) 30.8 (617) 26.0 (196)
Dyslipidemia, % (no.) 51.9 (1,043) 42.0 (319)
Family history of MI
and/or stroke/TIA, % (no.)
38.2 (768) 30.4 (231)
Hypertension, % (no.) 79.1 (1,590) 75.7 (575)
Obesity, % (no.) 30.6 (616) 31.6 (240)
Smoking, % (no.) 6.7 (135) 5.5 (42)
Concomitant diseases
Atrial fibrillation, % (no.) 72.7 (1,452) 63.6 (483)
Autoimmune disease, % (no.) 8.6 (170) 7.4 (56)
Chronic kidney disease, % (no.) 22.4 (447) 15.8 (120)
Chronic obstructive
pulmonary disease, % (no.)
21.0 (417) 15.6 (118)
Coronary artery disease, % (no.) 39.9 (773) 27.8 (210)
Depression, % (no.) 8.8 (176) 7.7 (58)
Heart failure, % (no.) 41.2 (813) 30.5 (230)
Liver disease, % (no.) 5.6 (112) 3.4 (26)
Myocardial infarction, % (no.) 20.0 (400) 12.2 (92)
Neoplasm, % (no.) 17.8 (354) 19.0 (142)
Peripheral artery disease, % (no.) 20.7 (408) 11.1 (84)
Sleep apnea, % (no.) 9.7 (186) 7.8 (58)
Stroke or TIA, % (no.) 17.3 (348) 17.5 (133)
Data are expressed as the relative and absolute frequencies for binary variables,
for normally distributed variables as median with 25th/75th percentile. Double
entries are possible for study participants in the coagulation service cohort with
prior treatment in regular medical care. TIA, Transient ischemic attack; MI,
Myocardial infarction. Significant difference between the groups (P <0.05) was
detected for hypertension, dyslipidemia, family history of MI/stroke/TIA, coronary
artery disease, myocardial infarction, heart failure, peripheral artery disease, atrial
fibrillation, chronic kidney disease, and liver disease.





Total amount of treatment days 4,681,125 931,579
Total amount of international





17.0 (10.7/26.0) 15.2 (11.4/18.8)
Self-management of oral
anticoagulant therapy
13.5 (271) 9.5 (72)
Physician in charge
General practitioner, % (no.) 67.6 (1,359) n.a.*
Specialist, % (no.) 32.3 (650) n.a.*
Home visits, % (no.) 6.8 (137) 8.8 (67)
Vitamin K antagonist in use
Warfarin, % (no.) 1.7 (34) 1.7 (13)
Phenprocoumon, % (no.) 98.3 (1,977) 98.3 (747)
Data are expressed as the relative and absolute frequencies for binary
variables. *Due to management of anticoagulation in the coagulation service
classification of “physician in charge” was not applicable in these patients.
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medical care, additional improvement of median TTR of
5.9% (77.6% (66.3/85.5) vs. 71.7% (61.1/86.6); P <0.001)
was detected together with a decrease of TTR variability
by 36% (20.3 vs. 13.0; P = 0.009). Frequency of stable antic-
oagulation control was 2.2-fold greater after coagulation
service treatment as compared to regular medical care
pretreatment (96.5% vs. 44.1%; P <0.001; Figure 1D). Qual-
ity of OAC therapy for the subsample of patients treated
with phenprocoumon did not differ from quality of the
overall sample of all VKA-treated patients (see Additional
file 1: Table S1).Indications for oral anticoagulation (OAC) therapy
Atrial fibrillation was the most frequent indication for
OAC in both cohorts. In comparison to venous thrombo-
embolism, which was the second frequent indication for
OAC, atrial fibrillation was 4.7-fold (regular medical care)
and 2.3-fold (coagulation service) more prevalent, respect-
ively. Quality of OAC differed between indications and
cohorts: in regular medical care, patients with prosthetic
heart valves showed the poorest anticoagulation control
whereas patients with atrial fibrillation achieved the high-
est level of TTR. In the coagulation service, distribution of
TTR among all indications for OAC presented a consist-
ent and ameliorated profile of TTR (except for other indi-
cations). Patients with a prosthetic heart valve showed the
most distinct difference in quality of therapy between both
cohorts with a ΔTTR of +24.6% in the coagulation service
cohort (Table 3).
Profile of time outside therapeutic range
The profile of the time outside therapeutic range in
both cohorts is depicted in Figure 2. In the regular med-
ical care cohort, the profile of time outside therapeutic
range presented an approximately 3-fold higher level of
under-anticoagulation (Figure 2A) as compared to over-
anticoagulation (Figure 2B; median frequency of under-
anticoagulation: 17.6% (4.2/35.5), median frequency of
over-anticoagulation: 6.4% (0/19.6)). In coagulation ser-
vice patients, the profile showed a more leveled balance
between over- and under-anticoagulation: the ratio of
under-treatment to over-treatment was 2.8 in regular
medical care and 0.6 in coagulation service patients
(4.7-fold reduction). The level of INR values below TTR
Figure 1 Quality of oral anticoagulation therapy in regular medical care and a telemedicine-based coagulation service. (A) Comparison of
quality of oral anticoagulation therapy in in patients of regular medical care and coagulation service. (B) Comparison of quality of oral anticoagulation
therapy in in patients of regular medical care and coagulation service in subsample of patients with stable anticoagulation control. (C) Intra-individual
comparison of quality of oral anticoagulation in patients treated first in regular medical care (blue) and afterwards in coagulation service (red). (D) Intra-
individual comparison of quality of oral anticoagulation in patients treated first in regular medical care (blue) and afterwards in coagulation service (red)
in subsample of patients with stable anticoagulation control. Time in therapeutic range is calculated according to linear interpolation method and
presented as median (first quartile/third quartile); P value for z-test. Mean TTR values are depicted graphically as asterisks within box-plots. TTR variability is
expressed by median absolute deviation, P value for Ansari-Bradley test. Absolute and relative frequency of stable oral anticoagulation control is depicted.
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Table 3 Distribution of indication for oral anticoagulation (OAC) and corresponding time in therapeutic range in
regular medical care and coagulation service
Indication for OAC Regular medical care Coagulation service
Frequency Time in therapeutic range Frequency Time in therapeutic range
Atrial fibrillation 66.2% (1,332) 67.5% (49.3/83.3) 61.1% (464) 75.0% (61.8/77.3)
Deep vein thrombosis 6.1% (123) 65.2% (46.8/75.3) 14.2% (108) 75.3% (66.1/85.0)
Peripheral vascular bypass surgery 8.0% (160) 64.9% (47.1/81.2) 2.2% (17) 74.9% (61.8/77.3)
Prosthetic heart valve 9.7% (195) 42.2% (30.4/68.3) 7.4% (56) 76.8% (63.0/82.8)
Pulmonary embolism 7.7% (154) 66.5% (50.6/82.6) 13.3% (101) 75.5% (64.7/84.7)
Others* 5.0% (100) 70.1% (54.3/82.1) 5.0% (38) 79.2% (59.8/88.0)
Patients can have more than one indication for oral anticoagulation (OAC) with vitamin K antagonist; indication is described in 2,011 of patients in regular medical
care and 760 patients in the coagulation service cohort. In coagulation service patients with pre-treatment in regular medical care, information on regular medical
care pre-treatment are described within regular medical care cohort (non-disjunct data). Frequency of indication is depicted as relative and absolute frequency.
Time in therapeutic range was calculated in patients with at least 4 months of anticoagulation treatment except self-management patients (1,160 patients in regular
medical care and 560 patients in coagulation service, respectively). *e.g., cerebral venous sinus thrombosis, Paget-Schrötter disease.
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ability of values below TTR was 2.6-fold higher in
regular medical care (P <0.0001). Levels of INR above
the TTR did not differ statistically between both cohorts
(P = 0.946).
Patients with self-management of oral anticoagulation
(OAC) therapy
In patients performing self-management of OAC, TTR was
detected to be at a higher level of quality in comparison to
physician-guided OAC in both regular medical care andFigure 2 Profile of time outside therapeutic range in regular medical
therapeutic range. (B) Relative frequency of time above therapeutic range. Bo
and coagulation service. Time outside therapeutic range is presented as medi
asterisks within box-plots. Variability of frequency outside therapeutic range iscoagulation service treatment. In these patients, a high
quality of therapy is obtained at the price of an approxi-
mately doubled frequency of INR control as compared
to regular patients. Overall, levels of median TTR were
higher for patients with self-management of OAC who
were affiliated to a coagulation service as compared to
regular medical care patients, although it did not reach
a level of statistical significance (84.8% (49.0/83.6) vs.
86.0% (62.9/84.2; P = 0.075). In self-management patients
associated to the coagulation service, variability of TTR
was 19.7% significantly lower (14.7 vs. 18.3; P = 0.031) andcare and coagulation service. (A) Relative frequency of time below
x-plots of profile of time outside therapeutic range of regular medical care
an (first quartile/third quartile); mean values are depicted graphically as
expressed by median absolute deviation, P value for Ansari-Bradley test.
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frequently in these patients (93.6% vs. 80.9%; Additional
file 2: Figure S1).
Time-dependent development of TTR
In both cohorts, development of TTR over time differed
significantly: in regular medical care, a decrease of TTR
of 0.053% per month was observed for the maximum
observation period of 35 months. In comparison, in the
coagulation service, an increase of 0.15% per treatment
months was detected (Figure 3). Besides a difference of
approximately 5.2% ΔTTR after 3 months of oral anti-
coagulants, an additional difference of 3.0% in TTR was
discovered after 12 months of treatment in coagulation
service patients (P for interaction <0.0001).
Discussion
In this study, a surprisingly high level of TTR in a popu-
lation predominantly treated with the long-acting VKA
phenprocoumon in a real-world setting of regular med-
ical care was obtained. Management of OAC therapy by
a specialized, telemedicine-based coagulation service was
able to substantially improve the quality of anticoagula-
tion therapy: higher levels of TTR were established for
all patients and for all indications. In addition, an increase
in the frequency of stable anticoagulation control and a
decrease of variability of TTR was observed.
The finding of high levels of TTR in this cohort with
phenprocoumon-based OAC in regular medical care
might be – at least in part – attributable to the use of
phenprocoumon as a long-acting VKA. In comparison to
short-acting acenocoumarol, phenprocoumon has beenFigure 3 Development of time in therapeutic range over time
in a specialized coagulation service in comparison to regular
medical care. Time in therapeutic range (TTR) is assessed according
to linear interpolation method. Median TTR values are depicted for
both cohorts for each time point. Values of regular medical care are
demonstrated in red, for coagulation service in blue.reported to be associated with higher levels of TTR in the
Netherlands [25]. This finding is of clinical relevance since
most evidence on OAC is derived from data on well-
investigated warfarin and extrapolated to other VKA. Me-
dian TTR in warfarin-driven, controlled clinical trials, in
which detailed control of therapy adherence was carried
out, was reported to be below 67% [26-28]. For commu-
nity practice, significantly worse quality of anticoagulation
control has been demonstrated in comparison to clinical
trials [9]: a meta-analysis of 8 studies with a total of
22,237 warfarin-treated patients reported TTR to be at
51% in community practice under warfarin treatment. Dif-
ferences in pharmacodynamics between short- and long-
acting VKA drugs may contribute to differences in vari-
ation of INR under therapy in favor of the longer acting
agents. This may indeed enable more stable anticoagula-
tion control with phenprocoumon as compared to the
shorter acting products. As previously described, patients
on phenprocoumon seem to require fewer monitoring
visits and have more stable INR values than patients
treated with short-acting VKA [29]. In addition, effects of
VKA-relevant genetic polymorphisms, e.g., CYP2C9 or
VKORC-1 polymorphism [30,31], might be less pro-
nounced in patients treated with phenprocoumon [16].
Interestingly, in the present analysis, the majority of
patients – especially in the coagulation service – pre-
sented stable anticoagulation control with higher than
average levels of TTR control. Against the background
that combined rates of bleeding and thromboembolism
are significantly lower in stable patients [32], these
data indicate that phenprocoumon-driven OAC may
provide high quality therapy, even in a non-specialized
setting.
Differences in TTR between indication groups re-
vealed that, especially in patients with prosthetic heart
valves who are treated in regular medical care, the qual-
ity of OAC was the worst in this patient collective in
regular medical care. Patients with these indications for
anticoagulation are known to have the highest risk for
life-threatening bleeding and thromboembolic events.
Hence, the significant increase of TTR in the coagulation
service seems highly clinically relevant. This is even more
important as application of NOACs for the indication of
mechanical heart valves is no valid option as yet, as
illustrated by the data of the recent RE-ALIGN study
demonstrating that the application of the novel direct
anticoagulant dabigatran was associated with increased
rates of thromboembolic and bleeding complications as
compared to standard VKA therapy [33]. Self-management
of OAC therapy is often performed by these patients, and
has been demonstrated to yield good quality of ther-
apy control. This finding is in line with a randomized
controlled trial on selected patients, which demon-
strated that the quality of patient self-management of
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at least for a selected group of patients [25,34].
The finding that a high level of quality of OAC can be
achieved by a specialized coagulation service for all
groups of patients is in line with results from other
European anticoagulation clinics: data from the Auric-
ulA investigators of the Swedish national quality registry
for anticoagulation and atrial fibrillation control repor-
ted a mean TTR of 76.2% for the participating anti-
coagulation centers in Sweden [14]. Management of
OAC by anticoagulation clinics appears to generate less
costs and provide greater effectiveness than usual care
[15]. These data are confirmed by reports from the
Netherlands where anticoagulation clinics achieve high-
quality OAC with low rates of adverse events [35]. Based
on the strong relation between time spent in therapeutic
range and clinical outcome [36-38], the reported differ-
ence in TTR between regular medical care and treatment
in a coagulation service in the present study is likely to be
translated into a reduction of adverse events [8,39]. A sub-
analysis of the RE-LY study stressed the interdependence
of quality of INR control and clinical outcome: although
non-inferiority of dabigatran was demonstrated to be pre-
sented at different levels of TTR control, high quality
VKA treatment at TTR >72.4% was shown to cause fewer
ischemic and hemorrhagic strokes. Depending on TTR,
dabigatran at a dose of 150 mg lost superiority over war-
farin in high TTR study centers regarding the reduction of
the risk of non-hemorrhagic stroke [40]. Optimization of
the profile of time outside therapeutic range, increase of
frequency of stable anticoagulation control, and less TTR
variability may additionally contribute to a reduction of
thromboembolic and bleeding events in coagulation ser-
vice patients [41]. However, prospective data on clinical
outcome of patients in both cohorts are necessary to val-
idate this intriguing finding.
In the coagulation service, which offers a multi-factorial
approach for comprehensive management of OAC ther-
apy, various aspects of the complexity of OAC have been
addressed, e.g., algorithm-driven phenprocoumon dosing
with respect to individual information in context to the
visit, patient education, and minimization of gaps in OAC
monitoring [42]. Key challenges, such as adherence to
therapy and medication, use of standard INR ranges, and
optimal treatment of comorbidities, have to be addressed
in order to obtain high quality of OAC. It seems elemen-
tary that any decision about VKA dose changes must
occur in the context of the anticoagulation visit and
reported patient information, also when using dosing
algorithms for TTR improvement. In the context of
demographic changes with an increasing amount of multi-
morbid patients and a still high level of OAC under-use,
especially in the elderly, future concepts for OAC will have
to address a variety of issues in a multimodal approach[3,43,44]. Therefore, a specialized coagulation service pro-
vides the unique potential to combine high quality OAC
together with continuous scientific evaluation; this may be
especially of importance for future considerations on the
management of OAC, also with respect to the introduction
of new OACs into clinical practice and an emerging neces-
sity for an evidence-based and individually-tailored OAC
therapy.
Strength and limitations
A major strength of the present study is the large-scale
investigation of quality of OAC therapy predominantly
performed with phenprocoumon in a real-life setting of
regular medical care and evaluation of its potential for
improvement in a specialized coagulation service. In con-
trast to most reports in the literature, all indications for
OAC are included in the present investigation. However,
the present analysis has several limitations. In this analysis,
calculation of the established surrogate parameter TTR is
performed to compare quality of OAC; although it is well-
recognized that efficacy and safety of OAC with VKA is
TTR-dependent [45], potential differences in clinical out-
come between patients treated in regular medical care and
a coagulation service can only be estimated. Extrapolation
of TTR values of a sample of predominantly white and
European ancestry to other populations should be done
with caution. TTR was calculated according to the widely
used interpolation method [7], nevertheless, gaps in INR
monitoring in the regular medical care cohort, which have
not been documented, cannot be ruled out. For methodo-
logical reasons, extreme ranges of INR values may bias
overall results. It was not analyzed how improvement of
TTR was achieved by the coagulation service. The poten-
tial of dosing algorithms to improve TTR has been de-
scribed in several studies [46-48]. Of course, there may be
other computer-assisted dosing algorithms than the one
investigated in the thrombEVAL study program that result
in even better INR adjustment. In regular medical care,
only patients with a minimum experience of 4 months of
OAC have been enrolled; therefore, development of TTR
after therapy initiation is not included in this analysis. Due
to the nature of an observational “real-world” study, selec-
tion and survival bias may limit the extrapolation of the
study results.
Conclusions
The key result of the current study is the demonstration
of an excellent high level of TTR using the long-acting
phenprocoumon in a telemedicine-based coagulation
service. Treatment in a coagulation service with a standard-
ized and multifactorial approach improved the quality of
therapy for patients regardless of indication of OAC. This
finding corroborates the importance of anticoagulation
clinics, which are pivotal for good quality anticoagulation
Prochaska et al. BMC Medicine  (2015) 13:14 Page 10 of 11with VKAs, but which presumably could also play a role
in the long-term management of NOACs. The latter is
underscored by recent reports on the association between
plasma levels of NOAC, in this case dabigatran, and clin-
ical outcomes, suggesting that individual tailoring towards
an optimal dose will be unavoidable [49-51]. For the tim-
bering of patients, properly managed treatment with
VKAs in a telemedicine-based setting seems a reasonable
alternative to unmonitored NOAC treatment. In addition,
monitoring of patients with NOAC in a telemedicine-
based setting may be an option for safe guidance of OAC
patients.
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Additional file 1: Table S1. Quality of oral anticoagulation therapy in
patients treated with phenprocoumon only. Treatment with phenprocoumon
was present in 1,977 of 2,011 patients in regular medical care and 723 of 760
patients in coagulation service. Calculation of TTR calculation was applicable in
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service. (A) Comparison of patients with self-management of oral
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(B) Subsample of self-management patients with stable anticoagulation
control. Time in therapeutic range is calculated according to linear
interpolation method and presented as median (first quartile/third
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asterisks within box-plots. *TTR variability is expressed by median
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frequency of stable oral anticoagulation control is depicted.
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